Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 10/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425398 | 0.94 | CDK4 (0.38) | SSTR5CDK4CKS1BSKP1SKP2 | |
| SCHEMBL2302078 | 0.88 | SSTR5 (0.41) | SSTR5CDK4GPR119USP30HRH3 | |
| SCHEMBL15034384 | 0.88 | SSTR5 (0.43) | SSTR5CDK4GPR119 | |
| SCHEMBL2302084 | 0.88 | SSTR5 (0.41) | SSTR5CDK4GPR119USP30HRH3 | |
| SCHEMBL2304087 | 0.88 | SSTR5 (0.41) | SSTR5CDK4GPR119USP30HRH3 | |
| SCHEMBL2301340 | 0.84 | MAPT (0.42) | SSTR5CDK4GPR119POLB | |
| SCHEMBL2302041 | 0.84 | SSTR5 (0.43) | SSTR5GPR119USP30NPY5R | |
| SCHEMBL2301254 | 0.81 | CDK4 (0.39) | SSTR5CDK4USP30 | |
| SCHEMBL2301251 | 0.81 | CDK4 (0.39) | SSTR5CDK4USP30 | |
| SCHEMBL2305887 | 0.81 | CDK4 (0.39) | SSTR5CDK4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |